BioSpace News Archive

Business

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

Virios Therapeutics, Inc. announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets.

May 5, 2022
·
4 min read
BioCapital

FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

May 5, 2022
·
12 min read
Business

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.

May 5, 2022
·
27 min read
Deals

Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments

Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept.

May 5, 2022
·
17 min read
Business

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and first quarter 2022 financial results.

May 5, 2022
·
9 min read
Pharm Country

SIGA Declares Special Dividend of $0.45 Per Share

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company.

May 5, 2022
·
6 min read
Business

Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Elevation Oncology, Inc. today announced financial results for the quarter ended March 31, 2022, and highlighted recent progress.

May 5, 2022
·
9 min read
BioMidwest

Revolo Biotherapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

Revolo Biotherapeutics announced that its management team will participate in the LifeSci Partners Immunology & Inflammation Symposium being held virtually May 10-11, 2022.

May 5, 2022
·
1 min read
Biotech Bay

CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

CODA Biotherapeutics, Inc. today announced that preclinical data from the Company’s focal epilepsy program will be featured as a poster presentation at the American Society of Gene & Cell Therapy 25th Annual Meeting being held virtually and in person, May 16-19, 2022, in Washington, D.C.

May 5, 2022
·
6 min read
Business

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. announced the strengthening of its oncology leadership team with the formation of a Scientific Advisory Board composed of key opinion leaders in oncolytic viruses and gene therapies.

May 5, 2022
·
7 min read